MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 598048 | Name: Thymopentin
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Thymopentin is a synthetic pentapeptide corresponding to the amino acids 32-36 of thymopoietin and exhibiting the full biological activity of the natural hormone. It is an immunomodulator which has been studied for possible use in the treatment of rheumatoid arthritis, AIDS, and other primary immunodeficiencies.

Chemical Structure

Thymopentin
Thymopentin
CAS#69558-55-0

Theoretical Analysis

MedKoo Cat#: 598048

Name: Thymopentin

CAS#: 69558-55-0

Chemical Formula: C30H49N9O9

Exact Mass: 679.3653

Molecular Weight: 679.77

Elemental Analysis: C, 53.01; H, 7.27; N, 18.54; O, 21.18

Price and Availability

Size Price Availability Quantity
10mg USD 500.00
100mg USD 1,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Thymopentin; ORF-15244; ORF 15244 ORF15244; TP-5; TP5; TP 5 Thymopoietin pentapeptide; Thymopentine;
IUPAC/Chemical Name
(6S,9S,12S,15S,18S)-1,6-diamino-9-(4-aminobutyl)-12-(carboxymethyl)-18-(4-hydroxybenzyl)-1-imino-15-isopropyl-7,10,13,16-tetraoxo-2,8,11,14,17-pentaazanonadecan-19-oic acid
InChi Key
PSWFFKRAVBDQEG-YGQNSOCVSA-N
InChi Code
InChI=1S/C30H49N9O9/c1-16(2)24(28(46)38-22(29(47)48)14-17-8-10-18(40)11-9-17)39-27(45)21(15-23(41)42)37-26(44)20(7-3-4-12-31)36-25(43)19(32)6-5-13-35-30(33)34/h8-11,16,19-22,24,40H,3-7,12-15,31-32H2,1-2H3,(H,36,43)(H,37,44)(H,38,46)(H,39,45)(H,41,42)(H,47,48)(H4,33,34,35)/t19-,20-,21-,22-,24-/m0/s1
SMILES Code
OC1=CC=C(C=C1)C[C@@H](C(O)=O)NC([C@H](C(C)C)NC([C@H](CC(O)=O)NC([C@H](CCCCN)NC([C@H](CCCNC(N)=N)N)=O)=O)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 679.77 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Chen Y, Tian H, Zhang X, Nice EC, Huang C, Zhang H, Zheng S. Copper- coordination driven brain-targeting nanoassembly for efficient glioblastoma multiforme immunotherapy by cuproptosis-mediated tumor immune microenvironment reprogramming. J Nanobiotechnology. 2024 Dec 28;22(1):801. doi: 10.1186/s12951-024-03059-2. PMID: 39731102; PMCID: PMC11681643. 2: Wang J, Tang Y, Zhao X, Ding Z, Ahmat M, Si D, Zhang R, Wei X. Molecular hybridization modification improves the stability and immunomodulatory activity of TP5 peptide. Front Immunol. 2024 Nov 11;15:1472839. doi: 10.3389/fimmu.2024.1472839. PMID: 39588365; PMCID: PMC11586334. 3: Li Q, Wu A, Zhang M, Zhang X, Zang H. Adaptive covalently assembled thymopentin/hyaluronic acid based anti-inflammatory drug carrier with injectability and controlled release. Int J Biol Macromol. 2024 Dec;282(Pt 3):136923. doi: 10.1016/j.ijbiomac.2024.136923. Epub 2024 Oct 28. PMID: 39490872. 4: Ji H, Fan Y, Long Y, Dai K, Zheng G, Jia X, Liu A, Yu J. Structural analysis of Salvia miltiorrhiza polysaccharide and its regulatory functions on T cells subsets in tumor-bearing mice combined with thymopentin. Int J Biol Macromol. 2024 Oct;277(Pt 1):133832. doi: 10.1016/j.ijbiomac.2024.133832. Epub 2024 Jul 11. PMID: 39002910. 5: Liu X, Xi R, Du X, Wang Y, Cheng L, Yan G, Lu H, Liu T, Li F. Thymopentapeptide Affects T-Cell Subsets by Modulating the Flora of the Skin Surface to Alleviate Psoriasis. Drug Des Devel Ther. 2024 Jul 4;18:2775-2791. doi: 10.2147/DDDT.S448550. PMID: 38984208; PMCID: PMC11231030. 6: Liu M, Svirskis D, Proft T, Loh J, Huang Y, Wen J. Cellular Uptake and Transport Mechanism Investigations of PEGylated Niosomes for Improving the Oral Delivery of Thymopentin. Pharmaceutics. 2024 Mar 14;16(3):397. doi: 10.3390/pharmaceutics16030397. PMID: 38543291; PMCID: PMC10975061. 7: Wen Z, Li H, Zhou C, Chen L, Zhang L, Chen Y, Zhang S, Pan X, Huang S, Shang W, Shen X, Liu Y, Liu J, Chen D. Thymopentin plays a key role in restoring the function of macrophages to alleviate the sepsis process. Int Immunopharmacol. 2024 Jan 5;126:111295. doi: 10.1016/j.intimp.2023.111295. Epub 2023 Dec 4. PMID: 38048668. 8: Ji H, Fan Y, Gao X, Gong Y, Dai K, Wang Z, Xu B, Yu J. The Protective Effects of Water-Soluble Alginic Acid on the N-Terminal of Thymopentin. Molecules. 2023 Sep 5;28(18):6445. doi: 10.3390/molecules28186445. PMID: 37764221; PMCID: PMC10536172. 9: Liu Y, Lu J. Mechanism and clinical application of thymosin in the treatment of lung cancer. Front Immunol. 2023 Aug 28;14:1237978. doi: 10.3389/fimmu.2023.1237978. PMID: 37701432; PMCID: PMC10493777. 10: Cao D, Qian K, Yang N, Xu G, Wang X, Zhu M, Wang Y, Li H, Shen J, Zhang Y, Cui Z. Thymopentin ameliorates experimental colitis via inhibiting neutrophil extracellular traps. Int Immunopharmacol. 2023 Nov;124(Pt A):110898. doi: 10.1016/j.intimp.2023.110898. Epub 2023 Sep 9. PMID: 37696141. 11: Yu PC, Hao CY, Fan YZ, Liu D, Qiao YF, Yao JB, Li CZ, Yu Y. Altered Membrane Expression and Function of CD11b Play a Role in the Immunosuppressive Effects of Morphine on Macrophages at the Nanomolar Level. Pharmaceuticals (Basel). 2023 Feb 13;16(2):282. doi: 10.3390/ph16020282. PMID: 37259426; PMCID: PMC9963077. 12: Ding N, He K, Tian H, Li L, Li Q, Lu S, Ding K, Liu J, Nice EC, Zhang W, Huang C, Tang Y, Shen Z. Carrier-free delivery of thymopentin-regulated injectable nanogels via an enhanced cancer immunity cycle against melanoma metastasis. Mater Today Bio. 2023 Apr 25;20:100645. doi: 10.1016/j.mtbio.2023.100645. PMID: 37206879; PMCID: PMC10189275. 13: Peng SJ, Feng Y, Li X, Wang XX, Wang Y, Zhou BT, Liu Y, Liu T, Wu YC. Thymopentin (TP-5) prevents lipopolysaccharide-induced neuroinflammation and dopaminergic neuron injury by inhibiting the NF-κB/NLRP3 signaling pathway. Int Immunopharmacol. 2023 Jun;119:110109. doi: 10.1016/j.intimp.2023.110109. Epub 2023 Apr 28. PMID: 37121113. 14: Sun MF, Liao JN, Jing ZY, Gao H, Shen BB, Xu YF, Fang WJ. Effects of polyol excipient stability during storage and use on the quality of biopharmaceutical formulations. J Pharm Anal. 2022 Oct;12(5):774-782. doi: 10.1016/j.jpha.2022.03.003. Epub 2022 Mar 24. PMID: 36320601; PMCID: PMC9615580. 15: Li X, Chen MM, Su HF, Zhang ML, Xie SY, Zheng LS. Real-Time Sniffing Mass Spectrometry Aided by Venturi Self-Pumping Applicable to Gaseous and Solid Surface Analysis. Anal Chem. 2022 Oct 11;94(40):13719-13727. doi: 10.1021/acs.analchem.2c01759. Epub 2022 Sep 29. PMID: 36173369. 16: Liu M, Svirskis D, Proft T, Loh J, Chen S, Kang D, Wen J. Exploring ex vivo peptideolysis of thymopentin and lipid-based nanocarriers towards oral formulations. Int J Pharm. 2022 Sep 25;625:122123. doi: 10.1016/j.ijpharm.2022.122123. Epub 2022 Aug 20. PMID: 35995317. 17: Nualkul M, Yuangsoi B, Hongoh Y, Yamada A, Deevong P. Improving the nutritional value and bioactivity of soybean meal in solid-state fermentation using Bacillus strains newly isolated from the gut of the termite Termes propinquus. FEMS Microbiol Lett. 2022 Jun 2;369(1):fnac044. doi: 10.1093/femsle/fnac044. PMID: 35536569. 18: Han YR, Wang TH, Gong WP, Liang JQ, An HR. Clinical Efficacy of a Combination of Thymopentin and Antituberculosis Drugs in Treating Drug-Resistant Pulmonary Tuberculosis: Meta Analysis. Ther Clin Risk Manag. 2022 Mar 25;18:287-298. doi: 10.2147/TCRM.S351317. PMID: 35386182; PMCID: PMC8977793. 19: Yu PC, Liu D, Han ZX, Liang F, Hao CY, Lei YT, Guo CR, Wang WH, Li XH, Yang XN, Li CZ, Yu Y, Fan YZ. Thymopentin-Mediated Inhibition of Cancer Stem Cell Stemness Enhances the Cytotoxic Effect of Oxaliplatin on Colon Cancer Cells. Front Pharmacol. 2022 Feb 15;13:779715. doi: 10.3389/fphar.2022.779715. PMID: 35242031; PMCID: PMC8886222. 20: Liu M, Svirskis D, Proft T, Loh JMS, Wen J. Preformulation studies of thymopentin: analytical method development, physicochemical properties, kinetic degradation investigations and formulation perspective. Drug Dev Ind Pharm. 2021 Oct;47(10):1680-1692. doi: 10.1080/03639045.2022.2048666. Epub 2022 Mar 15. PMID: 35234086.